Glaxo Drug Discovery and Development Research Grants (Including Microbicides); Deadline July 31May 30, 2003 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! GlaxoSmithKline will award research grants from $25,000 to $150,000 ($500,000 total) "for innovative HIV/AIDS drug research in recognition of the need to produce new alternatives and hope in the fight against the HIV/AIDS pandemic." These grants "are intended to further the development of inventive treatments for HIV/AIDS, including: therapies aimed at treating infection; prophylactic vaccines; or microbicides designed to prevent transmission of the virus." Applications will be judged by a panel of outside experts; recipients will be announced at the ICAAC conference in September 2003; and the grants will be paid by November 1. There is no obligation to license resulting technologies to Glaxo. For more information and application forms, visit www.dddresearchgrant.com or call 888-527-6935.
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
|
|